Advertisement

Topics

Novartis International AG: Novartis and Amgen announce FDA approval of Aimovig (erenumab), a novel treatment developed specifically for migraine prevention

19:29 EDT 17 May 2018 | FinanzNachrichten

Novartis International AG / Novartis and Amgen announce FDA approval of Aimovig (erenumab), a novel treatment developed specifically for migraine prevention . Processed and transmitted by Nasdaq Co...

Original Article: Novartis International AG: Novartis and Amgen announce FDA approval of Aimovig (erenumab), a novel treatment developed specifically for migraine prevention

NEXT ARTICLE

More From BioPortfolio on "Novartis International AG: Novartis and Amgen announce FDA approval of Aimovig (erenumab), a novel treatment developed specifically for migraine prevention"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...